E-viri
Recenzirano
Odprti dostop
-
Mlecnik, Bernhard; Bifulco, Carlo; Bindea, Gabriela; Marliot, Florence; Lugli, Alessandro; Lee, J Jack; Zlobec, Inti; Rau, Tilman T; Berger, Martin D; Nagtegaal, Iris D; Vink-Börger, Elisa; Hartmann, Arndt; Geppert, Carol; Kolwelter, Julie; Merkel, Susanne; Grützmann, Robert; Van den Eynde, Marc; Jouret-Mourin, Anne; Kartheuser, Alex; Léonard, Daniel; Remue, Christophe; Wang, Julia Y; Bavi, Prashant; Roehrl, Michael H A; Ohashi, Pamela S; Nguyen, Linh T; Han, SeongJun; MacGregor, Heather L; Hafezi-Bakhtiari, Sara; Wouters, Bradly G; Masucci, Giuseppe V; Andersson, Emilia K; Zavadova, Eva; Vocka, Michal; Spacek, Jan; Petruzelka, Lubos; Konopasek, Bohuslav; Dundr, Pavel; Skalova, Helena; Nemejcova, Kristyna; Botti, Gerardo; Tatangelo, Fabiana; Delrio, Paolo; Ciliberto, Gennaro; Maio, Michele; Laghi, Luigi; Grizzi, Fabio; Fredriksen, Tessa; Buttard, Bénédicte; Lafontaine, Lucie; Bruni, Daniela; Lanzi, Anastasia; El Sissy, Carine; Haicheur, Nacilla; Kirilovsky, Amos; Berger, Anne; Lagorce, Christine; Paustian, Christopher; Ballesteros-Merino, Carmen; Dijkstra, Jeroen; van de Water, Carlijn; van Lent-van Vliet, Shannon; Knijn, Nikki; Muşină, Ana-Maria; Scripcariu, Dragos-Viorel; Popivanova, Boryana; Xu, Mingli; Fujita, Tomonobu; Hazama, Shoichi; Suzuki, Nobuaki; Nagano, Hiroaki; Okuno, Kiyotaka; Torigoe, Toshihiko; Sato, Noriyuki; Furuhata, Tomohisa; Takemasa, Ichiro; Itoh, Kyogo; Patel, Prabhu S; Vora, Hemangini H; Shah, Birva; Patel, Jayendrakumar B; Rajvik, Kruti N; Pandya, Shashank J; Shukla, Shilin N; Wang, Yili; Zhang, Guanjun; Kawakami, Yutaka; Marincola, Francesco M; Ascierto, Paolo A; Fox, Bernard A; Pagès, Franck; Galon, Jérôme
Journal of clinical oncology, 11/2020, Letnik: 38, Številka: 31Journal Article
The purpose of this study was to evaluate the prognostic value of Immunoscore in patients with stage III colon cancer (CC) and to analyze its association with the effect of chemotherapy on time to recurrence (TTR). An international study led by the Society for Immunotherapy of Cancer evaluated the predefined consensus Immunoscore in 763 patients with American Joint Committee on Cancer/Union for International Cancer Control TNM stage III CC from cohort 1 (Canada/United States) and cohort 2 (Europe/Asia). CD3+ and cytotoxic CD8+ T lymphocyte densities were quantified in the tumor and invasive margin by digital pathology. The primary end point was TTR. Secondary end points were overall survival (OS), disease-free survival (DFS), prognosis in microsatellite stable (MSS) status, and predictive value of efficacy of chemotherapy. Patients with a high Immunoscore presented with the lowest risk of recurrence, in both cohorts. Recurrence-free rates at 3 years were 56.9% (95% CI, 50.3% to 64.4%), 65.9% (95% CI, 60.8% to 71.4%), and 76.4% (95% CI, 69.3% to 84.3%) in patients with low, intermediate, and high immunoscores, respectively (hazard ratio HR; high low, 0.48; 95% CI, 0.32 to 0.71; = .0003). Patients with high Immunoscore showed significant association with prolonged TTR, OS, and DFS (all < .001). In Cox multivariable analysis stratified by participating center, Immunoscore association with TTR was independent (HR high low, 0.41; 95% CI, 0.25 to 0.67; .0003) of patient's sex, T stage, N stage, sidedness, and microsatellite instability status. Significant association of a high Immunoscore with prolonged TTR was also found among MSS patients (HR high low, 0.36; 95% CI, 0.21 to 0.62; .0003). Immunoscore had the strongest contribution χ2 proportion for influencing survival (TTR and OS). Chemotherapy was significantly associated with survival in the high-Immunoscore group for both low-risk (HR chemotherapy no chemotherapy, 0.42; 95% CI, 0.25 to 0.71; = .0011) and high-risk (HR chemotherapy no chemotherapy, 0.5; 95% CI, 0.33 to 0.77; = .0015) patients, in contrast to the low-Immunoscore group ( > .12). This study shows that a high Immunoscore significantly associated with prolonged survival in stage III CC. Our findings suggest that patients with a high Immunoscore will benefit the most from chemotherapy in terms of recurrence risk.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.